REFERENCES:
1. Klimek L, Jutel M, Akdis C, et al. Handling of allergen immunotherapy
in the COVID‐19 pandemic: An ARIA‐EAACI statement. Allergy.2020;75(7):1546-1554.
2. Gelincik A, Demir S, Olgaç M, et al. High adherence to subcutaneous
immunotherapy in a real-life study from a large tertiary medical center.Allergy & Asthma Proceedings. 2017;38(6):78-84.
3. Reisacher WR, Visaya JM. Patient adherence to allergy immunotherapy.Current Opinion in Otolaryngology & Head and Neck Surgery.2013;21(3):256-262.
4. Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy:
therapeutic vaccines for allergic diseases A WHO position paper.Journal of Allergy and Clinical Immunology. 1998;102(4):558-562.
5. Durham SR, Leung DY. One hundred years of allergen immunotherapy:
time to ring the changes. Journal of Allergy and Clinical
Immunology. 2011;127(1):3-7.
6. Nelson HS. Advances in upper airway diseases and allergen
immunotherapy. Journal of allergy and clinical immunology.2003;111(3):793-798.
7. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test:
reliability, validity, and responsiveness in patients not previously
followed by asthma specialists. Journal of Allergy and Clinical
Immunology. 2006;117(3):549-556.
8. Bousquet P, Combescure C, Neukirch F, et al. Visual analog scales can
assess the severity of rhinitis graded according to ARIA guidelines.Allergy. 2007;62(4):367-372.
9. Demoly P, Bousquet P, Mesbah K, Bousquet J, Devillier P. Visual
analogue scale in patients treated for allergic rhinitis: an
observational prospective study in primary care: asthma and rhinitis.Clinical & Experimental Allergy. 2013;43(8):881-888.
10. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R.
Utilization and cost of immunotherapy for allergic asthma and rhinitis.Annals of Allergy, Asthma & Immunology. 1999;82(4):339-347.
11. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among
Medicaid-enrolled children with allergic rhinitis: patterns of care,
resource use, and costs. Journal of allergy and clinical
immunology. 2008;121(1):227-232.
12. More DR, Hagan LL. Factors affecting compliance with allergen
immunotherapy at a military medical center. Annals of Allergy,
Asthma & Immunology. 2002;88(4):391-394.
13. Pajno GB, Vita D, Caminiti L, et al. Children’s compliance with
allergen immunotherapy according to administration routes. Journal
of allergy and clinical immunology. 2005;116(6):1380-1381.
14. Kiel MA, Röder E, van Wijk RG, Al MJ, Hop WC, Rutten-van Mölken MP.
Real-life compliance and persistence among users of subcutaneous and
sublingual allergen immunotherapy. Journal of Allergy and Clinical
Immunology. 2013;132(2):353-360.
15. Egert-Schmidt A-M, Kolbe J-M, Mussler S, Thum-Oltmer S. Patients’
compliance with different administration routes for allergen
immunotherapy in Germany. Patient preference and adherence.2014;8:1475-1481.
16. Roberts G, Pfaar O, Akdis C, et al. EAACI guidelines on allergen
immunotherapy: allergic rhinoconjunctivitis. Allergy.2018;73(4):765-798.
17. Larenas-Linnemann DE, Epstein T, Ponda P, Bernstein D, Williams P,
Creticos P. Gaps in allergen immunotherapy administration and
subcutaneous allergen immunotherapy dose adjustment schedules: Need for
prospective data. Annals of Allergy, Asthma & Immunology.2020;125(5): 505–506.
18. Vaswani R, Garg A, Parikh L, Vaswani S. Non-adherence to
subcutaneous allergen immunotherapy: inadequate health insurance
coverage is the leading cause. Annals of Allergy, Asthma &
Immunology. 2015;115(3):241-243.
19. Celenk S, Bicakci A, Tamay Z, et al. Airborne pollen in European and
Asian parts of Istanbul. Environmental monitoring and assessment.2010;164(1-4):391-402.
20. Hoffmann TM, Acar Şahin A, Aggelidis X, et al. “Whole”
vs.“fragmented” approach to EAACI pollen season definitions: A
multicenter study in six Southern European cities. Allergy.2020;75(7):1659-1671.
21. Lower T, Henry J, Mandik L, Janosky J, Friday Jr G. Compliance with
allergen immunotherapy. Annals of allergy. 1993;70(6):480-482.
22. Rhodes BJ. Patient dropouts before completion of optimal dose,
multiple allergen immunotherapy. Annals of Allergy, Asthma &
Immunology. 1999;82(3):281-286.
23. Tinkelman D, Smith F, Cole 3rd W, Silk HJ. Compliance with an
allergen immunotherapy regime. Annals of allergy, asthma &
immunology: official publication of the American College of Allergy,
Asthma, & Immunology. 1995;74(3):241-246.
24. Pfaar O AI, Bonini M, Annaruth BH, et al. COVID-19 pandemic and
allergen immunotherapy – an EAACI survey. Allergy. 2021;
Manuscript submitted for publication.
Supplementary Table 1: Medication scores2